Nanobiotix SA
NBTX12.310USD
+2.107+20.66%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
583.55MMarktkapitalisierung
--KGV TTM
mehr Informationen über Nanobiotix SA Unternehmen
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Unternehmensinformationen
BörsenkürzelNBTX
Name des UnternehmensNanobiotix SA
IPO-datumOct 29, 2012
CEODr. Laurent Levy, Ph.D.
Anzahl der mitarbeiter108
WertpapierartDepository Receipt
GeschäftsjahresendeOct 29
Addresse60 rue de Wattignies
StadtPARIS
BörseNASDAQ Global Select Consolidated
LandFrance
Postleitzahl75012
Telefon33140260470
Websitehttps://www.nanobiotix.com
BörsenkürzelNBTX
IPO-datumOct 29, 2012
CEODr. Laurent Levy, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Enno Spillner
Mr. Enno Spillner
Independent Director
Independent Director
--
--
Dr. Alain Herrera
Dr. Alain Herrera
Independent Director
Independent Director
--
--
Dr. Louis Kayitalire, M.D.
Dr. Louis Kayitalire, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Brandon Owens
Mr. Brandon Owens
Vice President - Strategic Marketing and Corporate Communications
Vice President - Strategic Marketing and Corporate Communications
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Johnson & Johnson Innovation-JJDC, Inc.
11.86%
Geode Capital Management, L.L.C.
0.02%
Morgan Stanley & Co. International Plc
0.01%
Andere
88.11%
Aktionäre
Aktionäre
Anteil
Johnson & Johnson Innovation-JJDC, Inc.
11.86%
Geode Capital Management, L.L.C.
0.02%
Morgan Stanley & Co. International Plc
0.01%
Andere
88.11%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
11.86%
Investment Advisor/Hedge Fund
0.02%
Research Firm
0.01%
Investment Advisor
0.01%
Andere
88.10%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
25
5.76M
12.15%
-4.19M
2025Q1
25
5.76M
12.15%
-4.19M
2024Q4
25
6.07M
12.79%
-4.24M
2024Q3
21
6.42M
13.54%
-3.89M
2024Q2
22
9.30M
19.73%
-1.04M
2024Q1
21
9.31M
19.76%
-988.94K
2023Q4
21
9.28M
19.68%
+1.01M
2023Q3
16
4.47M
12.36%
+481.67K
2023Q2
12
3.47M
9.94%
-1.27M
2023Q1
11
3.46M
9.93%
-1.28M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Johnson & Johnson Innovation-JJDC, Inc.
5.62M
11.86%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
10.18K
0.02%
--
--
Mar 31, 2025
Morgan Stanley & Co. International Plc
6.10K
0.01%
+1.00K
+19.61%
Mar 31, 2025
UBS Financial Services, Inc.
3.00K
0.01%
-817.00
-21.40%
Mar 31, 2025
BNP Paribas Securities Corp. North America
661.00
0%
+661.00
--
Mar 31, 2025
RBC Capital Markets Wealth Management
136.00
0%
+7.00
+5.43%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
33.00
0%
--
--
Mar 31, 2025
Perceptive Advisors LLC
105.05K
0.22%
-161.04K
-60.52%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
